STOCK TITAN

QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director

(Positive)
Tags

QTREX Quantum (Nasdaq: QTEX) announced that on July 14, 2026 its Board of Directors appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately. She previously served as Vice President of R&D at Nano Dimension, where she led multidisciplinary AME-focused teams and co-authored IEEE research on AME-fabricated multi-metal-layer antenna architectures.

QTREX acquired the AME platform from Nano Dimension in April 2026 and is applying it to quantum connectivity and RF components. According to QTREX Quantum, Dr. Chappel-Ram’s appointment brings direct AME operating and scaling experience as the company advances from validated capability toward commercial component production.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

Set against an active Form F-3 resale registration for 6,666,667 ordinary shares where the company r...
Analysis

Set against an active Form F-3 resale registration for 6,666,667 ordinary shares where the company receives no resale proceeds, this director appointment mainly reinforces QTREX’s AME and quantum focus. Short interest remains relatively low, so attention may stay on integration progress and commercialization milestones rather than positioning dynamics.

Key Figures

Board appointment date: July 14, 2026 Digma GM start: January 2025 Digma VP R&D tenure: January 2021–December 2024 +1 more
4 metrics
Board appointment date July 14, 2026 Effective date of Dr. Shlomit Chappel-Ram’s appointment as independent director
Digma GM start January 2025 Start of Dr. Chappel-Ram’s role as General Manager of Digma Medical
Digma VP R&D tenure January 2021–December 2024 Period serving as Vice President R&D at Digma Medical
Nano Dimension tenure March 2019–December 2020 Period leading R&D programs at Nano Dimension Ltd.

Historical Context

5 past events · Latest: May 19 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
May 19 Name/ticker change Positive +2.1% Announced rebranding to QTREX Quantum and new Nasdaq ticker QTEX.
May 18 Medical device order Positive -5.8% Reported $580,000 purchase order for FDA-cleared ART100 from NYU Langone.
May 11 Strategy update Positive -6.3% CEO letter outlined AME focus, quantum connectivity plans and >$1M AME deals.
May 01 AME system sale Positive +5.8% Secured $596,000 AME system order from leading Irish technological university.
Apr 30 Partnership agreement Positive -0.9% Signed joint development agreement with Qarakal Quantum for cryogenic interconnects.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed share-price responses, with several positive commercial and strategic updates followed by negative one-day moves.

Key Terms

additively manufactured electronics, rf components, regulatory approval
3 terms
additively manufactured electronics technical
"a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing"
Additively manufactured electronics are electronic components and circuits created by layer-by-layer printing techniques instead of traditional machining or assembly. Think of building a cake where each layer can contain wiring, sensors or conductive traces so a finished part can combine structure and electronics in one piece. For investors, this can cut production time and part counts, enable custom or lightweight designs, and open new product opportunities or cost savings across manufacturing and supply chains.
rf components technical
"proprietary, application-specific RF components"
RF components are the physical parts that generate, shape, route and measure high‑frequency radio signals inside wireless systems — think antennas, amplifiers, filters, oscillators and switches. They matter to investors because their performance and cost determine how well wireless products work, how expensive they are to build, and how competitive a supplier can be; like engine parts for a car, small differences in these pieces can drive market share, margins and supply‑chain risk.
regulatory approval regulatory
"programs from early-stage development through regulatory approval and transfer to manufacturing"
Regulatory approval is the official permission given by government agencies or authorities that allows a product, service, or business activity to be legally operated or sold. It is important to investors because receiving approval often indicates that a product has been reviewed for safety and compliance, which can influence its success and the company’s prospects in the market. Without this approval, launching or selling certain products may be restricted or prohibited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Ness Ziona, Israel, July 17, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the “Board”) appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately.

Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd. (Nasdaq: NNDM), where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She also co-authored peer-reviewed IEEE research on AME-fabricated, multi-metal-layer antenna architectures.

As previously announced, QTREX acquired the AME platform from Nano Dimension Ltd. in April 2026 and is applying it to high-density, thermally optimized quantum connectivity and proprietary, application-specific RF components. Dr. Chappel-Ram’s appointment adds direct AME operating experience to the Board as QTREX advances its platform from a validated capability into commercial component production.

“We are adding to our Board an executive who played a foundational role in developing AME technology and fully recognizes the value it brings to quantum computing infrastructure,” said Dagi Ben-Noon, Chief Executive Officer of QTREX Quantum. “Dr. Chappel-Ram’s deep technical understanding and proven track record in scaling complex hardware directly match the operational phase QTREX is at today.”

Dr. Chappel-Ram has served as a General Manager of Digma Medical since January 2025, where she leads operations, product development, regulatory and clinical programs, fundraising, and investor communications. From January 2021 until December 2024 she also served as Digma Medical’s Vice President R&D and was leading Investor Relations activities. She previously held senior R&D roles at Edwards Lifesciences (Cardioband) and Medinol Ltd., alongside her tenure at Nano Dimension Ltd. from March 2019 until December 2020, where she directed complex technology programs from early-stage development through regulatory approval and transfer to manufacturing. Dr. Chappel-Ram serves as a consultant and advisory board of directors’ member at Kidron Capital since April 2021, and also served as a consultant and advisory board of director member at NGLi Holdings from March 2023 until March 2024. Her academic and professional training includes a Ph.D. in Chemistry, summa cum laude, and an MBA from Bar-Ilan University, postdoctoral work in Chemistry and Biochemistry at the City University of New York, and completion of the Directors and Senior Corporate Officeholders Program at Tel Aviv University’s LAHAV Executive Education.

“I have seen firsthand what AME can deliver when materials, electrical design and manufacturing are engineered as one integrated system,” said Dr. Chappel-Ram. “QTREX is applying these capabilities to the demanding connectivity requirements of scalable quantum hardware, and I look forward to contributing my experience as the Company advances development, qualification and commercial production.”

About QTREX Quantum
QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.

For more information, please visit: q-trex.com

Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the AME platform capabilities and advances; that Dr. Chappel-Ram’s appointment adds direct AME operating experience to the Board; that Dr. Chappel-Ram’s deep technical understanding and proven track record in scaling complex hardware directly match the operational phase QTREX is at today; and the belief that Dr. Chappel-Ram will contribute her experience as the Company advances development, qualification and commercial production . Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission.

Company Contact
QTREX Quantum
Email: info@q-trex.com
Phone: +972-9-9664485


FAQ

What did QTREX Quantum (Nasdaq: QTEX) announce about its Board on July 17, 2026?

QTREX Quantum announced the appointment of Dr. Shlomit Chappel-Ram as an independent director, effective July 14, 2026. According to QTREX Quantum, her experience in AME and complex hardware scaling aligns with the company’s move toward commercial quantum connectivity components.

Who is Dr. Shlomit Chappel-Ram, the new independent director of QTREX Quantum (QTEX)?

Dr. Shlomit Chappel-Ram is a veteran R&D executive with deep AME and medical device experience. According to QTREX Quantum, she was formerly Vice President R&D at Nano Dimension and currently serves as General Manager of Digma Medical, leading operations and clinical programs.

How is Dr. Shlomit Chappel-Ram connected to QTREX Quantum’s AME platform (QTEX)?

Dr. Chappel-Ram previously led AME R&D at Nano Dimension, from which QTREX acquired its AME platform in April 2026. According to QTREX Quantum, her appointment adds direct operating experience as the company applies AME to quantum connectivity and RF components.

What relevant experience does QTREX Quantum’s new director bring for quantum computing infrastructure?

She brings multidisciplinary AME development, antenna architecture research, and complex hardware scaling experience. According to QTREX Quantum, her background in integrating materials, electrical design, manufacturing, and regulatory pathways supports QTREX’s efforts in high-density, thermally optimized quantum connectivity components.

What is Dr. Shlomit Chappel-Ram’s professional and academic background before joining QTREX Quantum’s Board?

She has held senior roles at Digma Medical, Edwards Lifesciences (Cardioband), Medinol, and Nano Dimension. According to QTREX Quantum, she holds a Ph.D. in Chemistry (summa cum laude), an MBA from Bar-Ilan University, and completed Tel Aviv University’s LAHAV directors program.